Fosamax and Dermatitis bullous - a phase IV clinical study of FDA data

Summary:

Dermatitis bullous is reported as a side effect among people who take Fosamax (alendronate sodium), especially for people who are female, 60+ old, have been taking the drug for 1 - 2 years also take Atenolol, and have Chronic myeloid leukaemia.

The phase IV clinical study analyzes which people have Dermatitis bullous when taking Fosamax. It is created by eHealthMe based on reports of 104,411 people who have side effects when taking Fosamax from the FDA, and is updated regularly.

What is Fosamax?

Fosamax has active ingredients of alendronate sodium. It is often used in osteoporosis. eHealthMe is studying from 105,452 Fosamax users. Check the latest studies of Fosamax.

What is Dermatitis bullous?

Dermatitis bullous (inflammation of the skin characterized by the presence of bullae which are filled with fluid) is found to be associated with 662 drugs and 949 conditions by eHealthMe. Check the latest studies of Dermatitis bullous.

On Aug, 09, 2026

104,411 people reported to have side effects when taking Fosamax.
Among them, 33 people (0.03%) have Dermatitis bullous.

Among these 33 people:

How long have people been on Fosamax when they have Dermatitis bullous? *

What is the gender of people who have Dermatitis bullous when taking Fosamax? *

female: 93.75 %
male: 6.25 %

What is the age of people who have Dermatitis bullous when taking Fosamax? *

What are other drugs people take besides Fosamax? *

What are other side effects people have besides Dermatitis bullous? *

Cystitis Interstitial (unknown cause characterized by bladder pain): 6 people, 18.18%
Depression: 6 people, 18.18%
Osteomyelitis (infection of bone): 6 people, 18.18%
Stress And Anxiety: 6 people, 18.18%
Spinal Osteoarthritis (joint cartilage loss in spine): 6 people, 18.18%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 5 people, 15.15%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 5 people, 15.15%
Indigestion: 5 people, 15.15%
Chest Pain: 5 people, 15.15%
Back Pain: 5 people, 15.15%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 3.03%
Purine Metabolism Disorder: 1 person, 3.03%
Oesophagitis (inflammation of oesophagus): 1 person, 3.03%
Nail Tinea (fungal infection of nail): 1 person, 3.03%
Multiple Myeloma (cancer of the plasma cells): 1 person, 3.03%
Low Density Lipoprotein Increased (cholesterol increased in blood): 1 person, 3.03%
Depression: 1 person, 3.03%
Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 1 person, 3.03%

* Approximation only. Some reports may have incomplete information.

Do you take Fosamax and have Dermatitis bullous?

- Check whether Dermatitis bullous is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Fosamax:

Fosamax (105,452 reports)

Browse all side effects of Fosamax:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Dermatitis bullous:

Dermatitis bullous (662 drugs)

Browse all the conditions that are associated with Dermatitis bullous:

Dermatitis bullous (949 conditions)

Related publications that referenced our studies

Stuckey BG, Sallie R, "Alendronate-induced unmasking or deterioration of coeliac disease: a case series", Osteoporosis International, 2015 Jan .
Akasaka E, Kayo SJ, Nakano H, Ishii N, Hashimoto T, Sawamura D, "Diaminodiphenyl Sulfone-Induced Hemolytic Anemia and Alopecia in a Case of Linear IgA Bullous Dermatosis", Case reports in dermatology, 2014 Jan .
Lee WY, Sun LM, Lin MC, Liang JA, Chang SN, Sung FC, Muo CH, Kao CH, "A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study", PloS one, 2012 Dec .
Stuckey BG, Sallie R, "Alendronate-induced unmasking or deterioration of coeliac disease: a case series", Osteoporosis International, 2015 Jan .
Akasaka E, Kayo SJ, Nakano H, Ishii N, Hashimoto T, Sawamura D, "Diaminodiphenyl Sulfone-Induced Hemolytic Anemia and Alopecia in a Case of Linear IgA Bullous Dermatosis", Case reports in dermatology, 2014 Jan .
Lee WY, Sun LM, Lin MC, Liang JA, Chang SN, Sung FC, Muo CH, Kao CH, "A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study", PloS one, 2012 Dec .

How the study uses the data?

The study uses data from the FDA. It is based on alendronate sodium (the active ingredients of Fosamax) and Fosamax (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.